Page 11 - P4403.14_V91_YOUROTC_Book APRIL_2024 Northern Ireland PRINT
P. 11

IN THE KNOW: ALLERGY  11
                                                                                           OWN BRAND  11





              Allergy Brand Performance


              2023
                     Allergy Brand Performance
                                                                                                      Sponsored by
               Despite strong growth from challenger-brand Allevia, Piri continues to dominate the allergy market,
                     2023
               sustaining the leading market share.
              Allergy Brands – Value % Share of Total Market
              Total Coverage - STD w/e 05.08.23                                                                                   Sponsored by
              100%    Despite strong growth from challenger-brand Allevia, Piri continues to dominate the allergy market,
               90%    sustaining the leading market share.          ALL OTHER INCL. PL
                                                       33.2
                                                                    ALLEVIA
                                        35.0
               80%   Allergy Brands – Value % Share of Total Market
                         40.9
                                                                    POLLENASE
               70%   Total Coverage - STD w/e 05.08.23              STERIMAR
                     100%
                                                        9.6
               60%        0.2            6.0            0.0         OPTREX
                           -
                                         0.1
                                         1.0
                          1.0
                                                        0.9
               50%    90% 9.9            9.3            8.6         GALPHARM            ALL OTHER INCL. PL
                                                                    BENADRYL
                                                                        33.2
                                                        5.3
               40%    80% 4.7      40.9   5.4         35.0          CLARITYN            ALLEVIA
                          0.4
                          1.6
                                         0.4
                                         1.4
                                                        0.4
                          8.0            8.0            1.2         CLARINAZE           POLLENASE
               30%        1.0            0.7            8.9
                      70%                               0.6         BECODEFENCE         STERIMAR
               20%                                                  BECONASE
                      60% 28.9      0.2   28.3        6.0                9.6            OPTREX
                                     -
                                                      0.1
                                    1.0
                                                      1.0
                                                       26.2
                                                                         0.0
                                                                         0.9
               10%                                                  OTRIVINE            GALPHARM
                      50%                                           PIRI
                0%                  9.9               9.3                8.6            BENADRYL
                       STD 2021       STD 2022       STD 2023
                                       STD YA
                                                      STD TY
                       STD 2YA
                      40%           4.7               5.4                5.3            CLARITYN
                                    0.4
                                    1.6
                                                      0.4
                                                      1.4
                                                                         0.4
                                    8.0               8.0                1.2            CLARINAZE
                                                                         8.9
              The Peak period continues to gain importance, accounting for 62% of the season’s sales, while the
                      30%
                                    1.0
              post peak period is losing importance.  0.7                0.6            BECODEFENCE
                      20%
              Allergy – Value % Share of Allergy                                        BECONASE
                                   28.9
                                                      28.3
              Total Coverage  - STD split years by peaks w/e 05.08.2023  26.2           OTRIVINE
                      10%
                  31.5      29.2       29.3                    60.9       62.6          PIRI
                       0%                           56.8                               11.7      9.9
                                STD 2021           STD 2022           STD 2023                              8.1
                                                                      STD TY
                                 STD 2YA
                                                    STD YA
                     The Peak period continues to gain importance, accounting for 62% of the season’s sales, while the
                     post peak period is losing importance.
             Pre-Peak 2YAPre-Peak YAPre-Peak TY   Peak 2YA   Peak YA    Peak TY     Post Peak Post Peak YAPost Peak TY
                                                                                       2YA
                     Allergy – Value % Share of Allergy
               This year, syrup supply constraints held back growth in the Kids segment. Despite this, Piri syrups
                     Total Coverage  - STD split years by peaks w/e 05.08.2023
               continue to dominate the Kids segment.
               Kids and Adults – Value and Unit Sales                 Buying      60.9         62.6
                          31.5
                                                    29.3
                                       29.2
                                                                                    Trade
               Total Coverage - STD TY, YA, 2YA w/e 05.08.23   Size  56.8     RRP   Offer   POR    Pip Code    11.7
                             Product
                                                                       Price/
                                                                                          %
                                                                       Single        %                                      9.9
                             PIRI                                                                                                        8.1
                                 8.5%  PIRITON SYRUP 2MG/5ML      150ml  91.5% £6.50  7%  38%  022-0392
                                                                       £3.37
                                 -0.3%pts    PIRITON TABS 4MG   500  +0.3%          5%   36%   022-0434
                                                                             £38.00
                                                                      £20.26
                                             PIRITON TABS 4MG               30  £2.83  £5.50  8%  38%  213-2074
                           KIDS - Value Sales £m               70ml   £3.26  KIDS - Unit Sales (m)          Post Peak Post Peak YAPost Peak TY
                                               PIRITEZE SYRUP
                                                                              £6.49
                                                                                    10% 40%
                                                                                               301-7993
                                                                               Peak YA
                    Pre-Peak 2YAPre-Peak YAPre-Peak TY          60 Peak 2YA   £9.50  9%  39% Peak TY
                                             PIRITON TABS 4MG
                                                                                               333-9199
                                                                      £4.85
                                   £10.4m          £10.1m                             2.1m                     2YA
                                                                                                     1.8m
                                                                      £5.00

                    £8.1m              PIRINASE ALLERGY SPRAY       60 dose  1.7m  £9.50  9%  37%  359-0320
                      This year, syrup supply constraints held back growth in the Kids segment. Despite this, Piri syrups
                                                                              £9.50
                                                                                    10% 37%
                               PIRINASE HAYFEVER NASAL SPRAY   60 dose
                                                                      £5.00

                                                                                               377-3173
                      continue to dominate the Kids segment.
                           +27.7%          -2.4%                              +24.0%          -10.7%
                      Kids and Adults – Value and Unit Sales
                   STD 2YA         STD YA          STD TY            STD 2YA         STD YA          STD TY
                      Total Coverage - STD TY, YA, 2YA w/e 05.08.23
                                            8.5%                                          91.5%
                                            -0.3%pts                                      +0.3%
                                    KIDS - Value Sales £m                                          KIDS - Unit Sales (m)
                                               £10.4m              £10.1m                                     2.1m
                            £8.1m                                                          1.7m                                  1.8m
                                     +27.7%              -2.4%                                      +24.0%              -10.7%
                           STD 2YA             STD YA              STD TY                STD 2YA             STD YA             STD TY
   6   7   8   9   10   11   12   13   14   15   16